EMCDDA Treatment data collection strategy - progress report May 09 Dagmar Hedrich, on behalf of the TWG Presentation at the meeting of the Scientific Committee,

Slides:

Advertisements

Similar presentations

Strategy for the development of an African Science and Technology Policy framework By Dr. Abdul-Hakim Rajab Elwaer Director of HRST AUC AFRICAN UNION.

Advertisements

TREATMENT DATA INDICATORS IN THE UNODC DATA COLLECTION SYSTEM.

Dagmar Hedrich, Health and Social Responses EMCDDA expert meeting on TDI coverage, 5 February 2007 Treatment availability - ST 24 –

Overview of the 2011 Work Programme Paul Griffiths Scientific committee meeting, Lisbon, November 2010.

2 emcdda.europa.eu European drug report package A comprehensive analysis on the drugs problem in Europe.

6th Annual Progress Conference ISCH Domain 31 May – 1 June 2012 ENS Lyon.

Monitoring drug related overdose and mortality in Europe Dr. Eva Keller.

Overview of the 2010 work programme Paul Griffiths, Roland Simon, Rosemary de Sousa Scientific Committee meeting, Lisbon, November 2009.

Strenghtening collaboration with Serbia - IPA4 Project expected outcomes Frédéric Denecker, Programme Management Officer Reitox and International Cooperation.

30 June 2015, 17:10:39 FP7 Network of Focal Points in Egypt (to be) Yasser Elshayeb Technical Office Ministry of Higher Education and State for Scientific.

Drug use, related problems and interventions targeting drug users in prison in the European countries: main issues and challenges for the future Linda.

Research & Innovation Horizon societal challenge 1 Open Info Day Funding Opportunities for SMEs Horizon 2020 "Health, demographic change and wellbeing"

The REITOX Experience Lessons learned in developing a network of National Drugs Focal Points and challenges for the future Alan Lodwick, Head of UK National.

European Monitoring Centre for Drugs and Drug Addiction Margareta Nilson ISAJE, Helsinki, 1 September 2006.

Tim Pfeiffer-Gerschel, DBDD Dubrovnik, Jan 2008CARDS EWS CARDS 2004, Component 4 Early Warning System Tim Pfeiffer-Gerschel National Focal Point.

Whilst the pharmaceutical industry plays a key role in developing and producing medicines, there is a tension between industry’s need to expand product.

An EMCDDA view on recovery Roland Simon Head of Unit Intervention, Best Practice, and Scientific Partners.

Quality Assurance at the European Monitoring Centre for Drugs and Drug Addiction Sandrine Sleiman European Conference on Quality in Official Statistics,

Integrated Growth Pillar 1 of the SEE 2020 Strategy SEEIC Meeting Sarajevo, 19 June 2013.

Jennifer Hillebrand, „Rehabilitation of Drug Addicted Persons: Experience of Lithuania and European Countries”, 18 October 2007 Improving drug treatment.

Treatment system-based data collection: an integrated approach to monitoring Expert meeting: Implementation of the treatment strategy EMCDDA Lisbon,

HARM REDUCTION RESPONSES TO DRUGS IN THE EUROPEAN UNION – FROM MARGIN TO MAINSTREAM 8 th Annual Meeting of the European Red Cross / Red Crescent Network.

Annual report 2010: the state of the drugs problem in Europe.

Annual report 2009: the state of the drugs problem in Europe International Conference: New trends in drug use: facts and solutions, Parliament of the Republic.

Marina Kuzman, MD, PhD Croatian National Institute of Public Health National Drug Prevention and Information System in the Republic of Croatia - impact.

“Problem, intensive drug use and polydrug use” Introduction Danica Klempova, Scientific Committee meeting, Lisbon, 17 November.

ISPOR POLAND CHAPTER Polish Society of Pharmacoeconomics (PTFe )

An overview of European trends and developments Roland Simon ECAD Meeting 2011, Varna.

Twinning Project Implementation of Strategy for Fight Against Drugs in Serbia Kick off and Assessment November 2012 Belgrade.

Revision of Problem Drug Use indicator Danica Klempová and Julián Vicente 42nd Reitox HFP meeting, 27 May 2010.

Paul Griffiths and Roland Simon Wrap-up presentation What has the EMCDDA learned ?

ELDD Reflection – past, present and future 29th Meeting of the Scientific Committee, 18 Nov 2008.

Overview of EMCDDA’s Scientific Work Paul Griffiths, Roland Simon – Scientific committee Meeting, February 2008.

Single Convention on Narcotic Drugs Establishes a regulatory system for narcotic drugs government authorization is required for participation in the trade.

Linda Montanari, Buenos Aires, October 2003 CICAD/OAS, Demand Reduction Experts Group Meeting The Information System on Treatment Demand in EU EMCDDA.

EMCDDA Work Programme Key Issue 1: Key Indicators 30th Meeting of Scientific Committee J Vicente (together with D Olszewski, D Klempova, L Montanari,

Treatment Prevalence Project Background information Expert meeting Implementation of the treatment strategy – Module 1: TDI prevalence 24 June 2013.

World Health Organization

Overview of EMCDDA’s 2009 Scientific Work Programme Paul Griffiths, Roland Simon - REITOX Meeting, Lisbon, November 2007.

Integrating Evaluation into the Design of the Minnesota Demonstration Project Paint Product Stewardship Initiative St. Paul, MN May 1, 2008 Matt Keene,

Role of Policy in Behavior Change. Contents of the Lecture.

WOMEN PROFILE AND GENDER ANALYSIS IN TREATMENT DATA UNODC DATA.

Overview of the three-year work programme (2010–2012) Rosemary de Sousa, Roland Simon, Paul Griffiths 30th ScC meeting, June 2009.

Health Care Profiles in a Comparative Context Tim Miller January 19, 2007 Fourth Annual NTA Workshop.

Role of Policy in Behavior Change. Contents of the Lecture.

BEST PRACTICE PORTAL BEST PRACTICE PORTAL project presentation to the Scientific Committee Ferri et al Lisbon, 16th July 2010.

Monitoring and reporting on the drug phenomenon in Europe EMCDDA mandate and activities Wolfgang Götz, Scientific Committee, Palmela, 14 February 2008.

EMCDDA 2009 Conference Update Maria Moreira, November 2008.

Data quality and feedback from the assessment on 2000 and 2001 TDI data 1 EMCDDA, TDI meeting, 23/24 June 2003 Luis Royuela.

June 2009 Regulation on pesticide statistics Pierre NADIN ESTAT E1- Farms, agro-environment and rural development

First European conference on drug supply indicators, , Brussels – Feed-back Chloé Carpentier, Laurent Laniel, EMCDDA 33 rd meeting of the.

                 HTA: political and ethical perspectives Presentation to Forum on Pharmaceutical Policy in the Enlarged Europe at 7 th.

INTERREG IVC Project RECOMMEND

HEE Nursing Associate Programme

STANDARDISED METHODOLOGY FOR SURVEY OF DRINKING HABITS AND ALCOHOL RELATED HARM DEVELOPED IN PROJECT SMART EG on Alcohol and Substance Abuse (ASA.

Global Mechanisms for Reporting of Treatment Data

Freya Vander Laenen STRUCTURED SESSION Costs of drug treatment

WWater reuse Water Directors 24/11/2014 Nicola NOTARO

Mandate of the Eurostat Working Group

Commission Activities Eurostat : Latest developments

EU Marine Strategy DG Environment B.1.

Marleen De Smedt Geoffrey Thomas Cynthia Tavares

ICON-Institute Public Sector

15 June 2009 EMCDDA activities ~ Supply Reduction

Natura 2000 management group Brussels, 19 May 2011

WWater reuse SCG Water Reuse 1/10/2014 Dagmar BEHRENDT KALJARIKOVA

NDPHS Work Plan for 2012 NDPHS 8th Partnership Annual Conference

Skopje, 21 November 2017, General Population Survey results– launch

TEDI project (Trans European Drug Information)

EU Drugs Action Plan: Guidelines and standards

Presentation transcript:

EMCDDA Treatment data collection strategy - progress report May 09 Dagmar Hedrich, on behalf of the TWG Presentation at the meeting of the Scientific Committee, 15 June 2009

Historical changes in treatment have taken place in the past decades in Europe, e.g. Opioid substitution develops into the major response to opioid use: 9-fold increase of OST from Diversification of pharmacological treatment approaches opioid dependence “Normalisation”: Increasing role of office- based (GP) treatment More attention to stimulants and other non-opioid treatment Treatment in prison no longer confined to ‘prison treatment units’

Diversification of data sources on drug treatment Treatment monitoring systems (based on TDI) well established Substitution ‘registries’ of some sort [Data on sales of relevant pharmaceutical substances - available nat level] Reimbursement statistics, Health insurance data, hospital statistics + technological innovations in monitoring

Treatment working group Chair: Roland Simon Start: Summer 2007 Members: up to 10, both scientific units involved Submission of draft proposal to NFPs: May 2009 Input and discussion: November 2009

Structure of draft document Historical perspective Context and objectives EMCDDA Mission EU AP Conceptual framework Treatment need / needs; treated population; availability; quality/outcome Status-quo: current collection instruments Aims, periodicity, achievements and limitations Future development of data collection

TDI ST 24 Access to treatment SQ 27 treatment quality SQ 27 treatment programmes

Annual Report Action PlanTreatment Profiles Stats Bull Tables Action Plan TDI SQ 27 - Treatment Programmes BP Portal EUROPEAN TREATMENT EXPERTS ST 24 – Access to Treatment Annual Report SQ 27 -Quality Stats Bull Tables Action Plan Annual ReportBP Portal Treatment profiles

Thank you for your attention.

EMCDDA data collection tools on access to drug treatment TDI: First treatment in life and first treatment in reporting year; Clients in continuous treatment (pilot) NEW in 2008 ST24: NEW in 2008 Estimates on overall level of treatment provision (individuals or episodes / PDUs / POUs). Estimates on opioid substitution/maintenance treatment Information on data flow betw register/client information systems substitution/maintenance treatment and TDI

Definition of “treatment” TDI protocol: “Drug treatment is defined as any activity that directly targets individuals who have problems with their drug use and which aims to improve the psychological, medical or social state of those who seek help for their drug problem”. ST 24 and SQ 27: … treatment comprises all structured interventions with specific pharmacological and/or psychosocial techniques aiming at reducing or abstaining from the use if illegal drugs Services provided at IN/OUTpatient drug treatment agencies